Using a special imaging agent to detect meningioma during surgery
Official title: A Pilot Study to Evaluate Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
Run by Weill Medical College of Cornell University · NCT06377371 · Data updated 2026-11-12
This study is testing a special imaging agent to see if it can help doctors find meningioma tumors during surgery for patients who are having them removed.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | September 11, 2024 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | February 27, 2026 |
| Trial ID | NCT06377371 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with a high suspicion of meningioma requiring surgical resection based on MRI findings.
✕Probably not a fit
Patients who may not benefit include those undergoing specific surgical procedures where the neoprobe cannot be used or those with contraindications to MRI.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study aims to evaluate the feasibility of using [Cu64]DOTATATE for intraoperative detection of meningioma tumors. The study will involve 20 patients diagnosed with meningioma who are candidates for surgical resection, utilizing a gamma probe device to trace tumors after injection of the imaging agent. The study will also correlate intraoperative findings with pathology markers and assess the integration of this technique into surgical workflows. Additionally, it seeks to identify which surgical candidates may benefit most from this approach based on tumor characteristics.
Why it matters
Potential benefit: If successful, this approach could enhance the accuracy of tumor detection during surgery, potentially leading to better surgical outcomes for patients with meningioma.
How similar studies have gone: While this approach is innovative, similar studies using intraoperative imaging techniques have shown promise in other tumor types, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * High suspicion of meningioma necessitating surgical resection based on conventional MRI criteria, or diagnosis of meningioma based on pathology reports from prior resection with radiographic findings of suspected recurrent or residual tumor necessitating repeat surgery. Exclusion Criteria: * Pregnant or breastfeeding * Patients undergoing endoscopic endonasal resection, eyebrow incision surgery, or any surgical procedure in which the neoprobe cannot be employed * Patients with hypersensitivity to somatostatin analogs * Patients with contraindications to conventional MRI * Patients with prior history of cranial radiation therapy * Patients currently enrolled in other therapeutic clinical trials related to meningioma will be excluded
Where it's running
-
New York-Presbyterian/Weill Cornell Medical Center
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Jana Ivanidze, MD/PhD — Weill Medical College of Cornell University
- Study coordinator: Jana Ivanidze, MD/PhD
- Email: jai9018@med.cornell.edu
- Phone: 212-746-4587
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Combination therapy with IN10018 and dalpiciclib for progressive meningioma
This phase 1 study tests whether taking IN10018 with dalpiciclib is safe and tolerable in adults with growing meningiomas to see if the combo can help control the tumor.
-
JZP3507 (ONC206) for recurrent Grade 2/3 meningioma
A pill-based therapy (JZP3507) is being tested to see if it can help adults with recurrent grade 2 or 3 meningioma who have not benefited from standard treatments.
-
Panitumumab-IRDye800 for guiding brain tumor surgery
A tiny dose of panitumumab-IRDye800 is tested to see if it helps visualize brain tumors during surgery in adults.
-
Zanzalintinib for recurrent or progressive meningioma
This trial tests whether zanzalintinib can help people whose meningioma has come back or kept growing after standard treatments.
-
Meningioma: How social factors and personal risks relate to health outcomes
This study tests whether social and personal risk factors help explain differences in health outcomes for adults with meningioma.
-
Skin closure after brain tumor surgery: running absorbable versus interrupted non-absorbable sutures
This will test whether absorbable running intradermal sutures or non-absorbable interrupted transdermal sutures produce better wound healing after craniotomy in adults with supratentorial brain tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.